Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $62 from $60 and keeps an Overweight rating on the shares. The firm increased estimates for the company ahead of the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS: